Seattle genetics to host conference call and webcast discussion of first quarter 2016 financial results on april 28, 2016

Bothell, wash.--(business wire)--seattle genetics, inc. (nasdaq: sgen) announced today that it will report its first quarter 2016 financial results on thursday, april 28 after the close of financial markets. following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. access to the event can be obtained as follows: live access on thursday, april 28, 20161:30 p.m. pacific time / 4:30 p.m. eastern time telephone 800-499-4035 (domestic) or 416-204-9269 (international); conference id 4267568 webcast available at www.seattlegenetics.com in the investors and news section replay access telephone replay will be available beginning at approximately 4:30 p.m. pt on thursday, april 28, 2016 through 5:00 p.m. pt on monday, may 2, 2016 by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference id 4267568 webcast replay will be available on the seattle genetics website at www.seattlegenetics.com in the investors and news section about seattle genetics seattle genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. seattle genetics is leading the field in developing antibody-drug conjugates (adcs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. the company’s lead product, adcetris® (brentuximab vedotin), is a cd30-targeted adc that, in collaboration with takeda pharmaceutical company limited, is commercially available in more than 60 countries, including the u.s., canada, japan and members of the european union. additionally, adcetris is being evaluated broadly in more than 70 ongoing clinical trials in cd30-expressing malignancies. seattle genetics is also advancing vadastuximab talirine (sgn-cd33a; 33a), an adc that is expected to advance into a phase 3 trial for acute myeloid leukemia in 2016. beyond adcetris and 33a, the company is developing a robust pipeline of clinical-stage programs, including denintuzumab mafodotin (sgn-cd19a; 19a), sgn-liv1a, asg-15me, asg-22me (enfortumab vedotin), sgn-cd70a, sea-cd40 and sgn-cd19b. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys (an affiliate of astellas), bayer, genentech, glaxosmithkline and pfizer. more information can be found at www.seattlegenetics.com.
SGEN Ratings Summary
SGEN Quant Ranking